Bristol-Myers Squibb Co vs Valero Energy Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B), while Valero Energy Corporation trades at $329.43 (market cap $93.27B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | VLO | |
|---|---|---|
Market Cap | $129.94B | $93.27B |
Sector | Health | Energy |
52-Week High | $65.89 | $323.92 |
52-Week Low | $42.60 | $133.38 |
Enterprise Value | $163.92B | $96.74B |
Dividend Yield | 3.96% | 1.48% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Valero Energy (VLO) trades at $328.43, up 4.28% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with key resistance at $329 and support at $319. Recent Q2 2026 results significantly exceeded expectations with EPS of $12.54 versus $10.11 estimates, driven by robust refining margins and renewable diesel performance. Revenue trends show recovery from 2025's $122.7B to projected $139.4B in 2026.
VLO presents a compelling value opportunity with attractive valuation metrics (P/E 13.51, P/S 0.7) and strong profitability (ROE 29.31%). Analyst consensus favors Buy ratings (55.55%) with $324.27 price target. Key risks include refining margin volatility and geopolitical impacts on oil markets. The company's disciplined capital allocation and dividend payments ($1.20 quarterly) provide shareholder returns amid energy sector transformation.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →